DXCM - DexCom: A Wealth Compounder In Healthcare
2024-02-14 00:14:02 ET
Summary
- DexCom reported strong financial growth in the fourth quarter of 2023, with worldwide revenue reaching $1.035 billion.
- The company is focused on expanding its global presence and advancing its technological capabilities, including the upcoming launch of Stelo, a CGM specifically designed for people with type 2 diabetes.
- DXCM expects sustained long-term growth, with guidance anticipating total revenue in the range of $4.15 to $4.35 billion for 2024.
Introduction
It's time to talk about one of the most interesting healthcare stocks on my radar.
Last year, I started covering DexCom, Inc. ( DXCM ) , the producer of medical devices from San Diego, California....
DexCom: A Wealth Compounder In Healthcare